scholarly journals GATA3 - IS IT A PROGNOSTIC MARKER IN BREAST CARCINOMA?

2021 ◽  
Vol 9 (01) ◽  
pp. 1008-1012
Author(s):  
Anum Khan
Keyword(s):  
Breast Carcinoma ◽  
Prognostic Marker ◽  
Tumor Size ◽  
Sampling Method ◽  
Tumor Grade ◽  
Nodal Status ◽  
Study Patient ◽  
Area Of Interest ◽  
Gata3 Expression ◽  
Quantitative Correlational Study

GATA binding proteins are among the new prognostic factors being explored. My area of interest is GATA3 to correlate it with tumor size, nodal status ,tumor grade, Estrogen receptor, Progesterone receptor and HER2neu receptors in breast carcinoma patients This was a quantitative correlational study Patient were enrolled using consecutive non probability sampling method. GATA3 was inversely related with tumor size ,nodal status and grade. Estrogen positivity was associated with higher GATA3. However Progesterone and HER2Neu receptors statuses did not show any significant association with GATA3 levels. This study concludes that GATA3 expression can be used as a prognostic marker of breast cancer.

scholarly journals Role of p53 as a prognostic marker in breast carcinoma and its correlation with tumor size, tumor grade and lymph node metastasis

2020 ◽  
Vol 7 (3) ◽  
pp. 378-383
Author(s):  
Alok Mohan ◽  
◽  
Bharat Jindal ◽  
Rajender Kumar Thakral ◽  
Vaseem Ansari ◽  
...  
Keyword(s):  
Lymph Node ◽  
Breast Carcinoma ◽  
Lymph Node Metastasis ◽  
Prognostic Marker ◽  
Tumor Size ◽  
Tumor Grade ◽  
Node Metastasis

scholarly journals Correlation of primary tumor size and axillary nodal status with tumor suppressor gene p53 in breast carcinoma

2002 ◽  
Vol 59 (1) ◽  
pp. 29-32 ◽  
Author(s):  
Brano Topic ◽  
Nebojsa Stankovic ◽  
Dragutin Savjak ◽  
Slavko Grbic
Keyword(s):  
Prognostic Factors ◽  
Breast Carcinoma ◽  
Tumor Suppressor ◽  
Tumor Suppressor Gene ◽  
Tumor Size ◽  
Primary Tumor ◽  
Suppressor Gene ◽  
Nodal Status ◽  
Primary Tumor Size ◽  
Tumor Suppressor Gene P53

Correlation of standard path morphological prognostic parameters, primary tumor size and axillary nodal status with new prognostic factor in breast carcinoma: tumor suppressor gene p53 was analyzed. The studied sample included 65 women who underwent surgery for breast carcinoma at the Surgical Clinic of Clinical Center Banja Luka, from January 1st 1997 till January 1st 1999. Statistical data analysis was performed and correlation of prognostic factors was determined. The majority of authors in this field agree that the primary tumor size and axillary nodal status are the two most important prognostic factors. These factors are the best predictors of prognosis and survival of women who had the tumor and were operated on. Tumor markers were immunohistochemically determined in the last ten years and, according to the majority of authors, are still considered the additional or relative prognostic factors in breast carcinoma. Their prognostic value and significance increase almost daily. Most frequently determined tumor markers are bcl-2, pS2, Ki-67 and p53. There was a positive, directly proportional relationship between primary tumor size and tumor suppressor gene p53, but there was no positive correlation between the axillary nodal status and tumor suppressor gene p53. Significance of determination of new tumor markers as the prognostic factors was emphasized. These markers represent a powerful tool in the early detection and prevention of breast carcinoma.

SEER study of breast cancer specific mortality (BCSM) in patients with lobular tumors treated based on recurrence score results.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 11568-11568
Author(s):  
Frederick L. Baehner ◽  
Steven Shak ◽  
Dave P. Miller ◽  
Valentina I. Petkov
Keyword(s):  
Breast Cancer ◽  
Tumor Size ◽  
Multivariable Analysis ◽  
Recurrence Score ◽  
Tumor Grade ◽  
Nodal Status ◽  
Large Sample Size ◽  
Lobular Breast Cancer ◽  
Gene Assay ◽  
Actuarial Methods

11568 Background: Linking the 21-gene assay RS result to the SEER Registries demonstrated very low 5-y BCSM with low RS and high 5-y BCSM with high RS across subgroups, such as nodal status, age, tumor size and grade (npj Breast Cancer 2016). Given the large sample size and interest in outcomes as a function of tumor characteristics, we characterized the relationship between RS results and BCSM in patients reported by SEER with lobular morphology. Methods: Patients with RS and lobular morphology based on the registry ICD-O-3 code 8520 were eligible if node negative (N0) or node positive up to 3 positive nodes (N+mic,1-3), HR+, HER2- negative, no prior malignancy, and diagnosed between Jan 2004 and Dec 2012. No information in SEER is available regarding lobulars, ie., trabecular, alveolar, solid and pleomorphic. 5-y BCSM was estimated using actuarial methods. Results: There were 6,075 eligible patients reported with lobular morphology (11% of cases). Median age was 59 years; 88%/12% were N0/N+; 31%/62%/7% grade 1/2/3; 61%/39% ≤2 cm/>2 cm. Median follow-up was 44 months. A minority (8%) had RS >25. Chemotherapy (CT) use and BCSM increased with increasing RS. In multivariable analysis in N0 disease, continuous RS result and tumor size predicted BCSM (p=0.003 and p=0.04, respectively), whereas age and tumor grade were non-significant. In multivariable analysis in N+ disease, continuous RS result alone predicted BCSM (p=0.002). Conclusions: In these analyses the prognosis of patients with lobular breast cancer treated based on RS results depends on both nodal status and the RS result. The 5-y BCSM for lobular breast cancer is excellent with RS of 25 or less, and increases for RS >25. [Table: see text]

scholarly journals Significance of Immunohistochemical Biomarker in Breast Carcinoma from a Single Tertiary Care Hospital of Southern Assam

2021 ◽  
Author(s):  
Naiding Momota ◽  
Choudhury Biswadeep ◽  
Bezbaruah Babul ◽  
Nivedita Dasgupta ◽  
Deuri Biman ◽  
...  
Keyword(s):  
Lymph Node ◽  
Breast Carcinoma ◽  
Tumor Size ◽  
Tertiary Care Hospital ◽  
Histological Grade ◽  
Statistical Significance ◽  
Tertiary Care ◽  
Tumor Grade ◽  
Lymph Node Status ◽  
Care Hospital

Abstract Background: Breast carcinoma is the most common malignancy in female worldwide, leading cause of death in women.immunohistochemistry plays a very important role in the prognostication and treatment determination of breast carcinoma patients. Objective: To analyze the immunohistochemical markers in invasive carcinoma of breast and to correlate the expression of hormonal receptors with age of the patient, tumor size, histological grade and lymph node metastasis.Materials and method: The study was conducted on 88 infiltrating ductal breast carcinoma sample in a tertiary care hospital of Southern Assam for a period of two year (January2018- December 2019). Data including age, tumor size, and histologic grade and lymph node status retrieved from pathology department. Chi- square was used to determine the statistical significance between ER/PR status HER2/neu status along with their correlation with various clinicopathological parametres with respect to infiltrating ductal breast carcinoma.Result: The mean age of the patients was 56.6 years. We observed correlation between ER and PR expression with age, tumor size, tumor grade. There was correlation between HER2/neu expression and age only. None of the markers showed correlation with lymph node involvement (P>0.05).Conclusion: Our findings showed the importance of biomarkers (ER, PR, HER2/neu) expression as prognostic factors for therapeutic decision.

Identification of risk factors in mammographically occult contralateral breast carcinoma detected by magnetic resonance imaging (MRI)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 614-614
Author(s):  
J. R. Bernard ◽  
L. A. Vallow ◽  
S. Packianathan ◽  
D. G. Feigel ◽  
E. R. DePeri ◽  
...  
Keyword(s):  
Risk Factors ◽  
Breast Carcinoma ◽  
Tumor Size ◽  
Menopausal Status ◽  
Contralateral Breast ◽  
Nodal Status ◽  
Newly Diagnosed ◽  
Receptor Status ◽  
Her 2 ◽  
Contralateral Carcinoma

614 Background: An analysis of preoperative bilateral breast MRI at our institution suggests that approximately 1/3 of patients with newly diagnosed breast cancer may have a mammographically occult, but MRI-evident, contralateral breast abnormality. A number of these patients will have pathologic confirmation of carcinoma in the contralateral breast. Identification of risk factors to predict which patients are at high risk for having a mammographically occult contralateral carcinoma was performed. Methods: MRI results of 401 women with newly diagnosed breast carcinoma who underwent MRI were reviewed (overall group; OG). Patients with a contralateral abnormality identified only by MRI were analyzed to determine the incidence of contralateral carcinoma. In addition, the following risk factors were evaluated: Age at diagnosis, menopausal status, tumor size, nodal status, ipsilateral tumor histology, tumor grade, hormone receptor status, Her-2/neu receptor status, and whether the patient had a palpable vs. mammographically detected abnormality. Results: Pathologically confirmed contralateral carcinoma (CC) was found in 13 patients (3.2%). Similar percentages of patients in both groups (OG and CC) were noted in regard to tumor size, histology, grade, nodal status, Her-2/neu receptor status, and method of detection (palpable vs. mammographic). However, median patient age was 71 (CC) vs. 62(OG); 92% (12/13) were postmenopausal (CC) compared to 75% (OG); and 100% were ER positive (CC) vs. 81% percent (OG). Conclusions: Older, postmenopausal women who have ER + tumors may have a higher likelihood of having synchronous, contralateral, mammographically occult, MRI-detected breast carcinoma. Preoperative MRI may be beneficial in patients with similar risk factors; however, further follow up and additional experience is needed for confirmation of these findings. No significant financial relationships to disclose.

CA 15–3: A Prognostic Marker in Breast Cancer

2000 ◽  
Vol 15 (4) ◽  
pp. 330-333 ◽  
Author(s):  
M.J. Duffy ◽  
S. Shering ◽  
F. Sherry ◽  
E. McDermott ◽  
N. O'Higgins
Keyword(s):  
Breast Cancer ◽  
Multivariate Analysis ◽  
Prognostic Marker ◽  
Tumor Size ◽  
Recurrent Breast Cancer ◽  
Serum Marker ◽  
Nodal Status ◽  
Prognostic Impact ◽  
Transmembrane Glycoprotein ◽  
A Prospective Study

CA 15–3 (also known as MUC1) is the most widely used serum marker in breast cancer. MUC1 is a large transmembrane glycoprotein which is frequently overexpressed and aberrantly glycosylated in cancer. Physiologically, MUC1 appears to play a role in cell adhesion and the high levels present in cancer may be causally involved in metastasis. At present the main uses of CA 15–3 are in preclinically detecting recurrent breast cancer and monitoring the treatment of patients with advanced breast cancer. In a prospective study of 368 patients we show that patients with high preoperative levels of CA 15–3 (>30.4 U/mL) had a worse outcome than patients with low levels of the marker. In multivariate analysis CA 15–3 as a prognostic marker was independent of both tumor size and nodal status. Furthermore, in multivariate analysis the prognostic impact of CA 15–3 was stronger than that of tumor size and at least as strong as nodal status. CA 15–3 may thus be the first independent prognostic serum marker in breast cancer.

Evaluation and Reinforcement of the Correlation of S-Phase Fraction with Nodal Metastases, Tumor Grade and Tumor Size in Breast Carcinoma Patients in Pakistan

2001 ◽  
Vol 197 (8) ◽  
pp. 531-536 ◽  
Author(s):  
Humayun Bakhtawar ◽  
Naureen Munawar Ali ◽  
Shaista Khan ◽  
Syed Abdul Aziz ◽  
Tariq Sliddiqui ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Tumor Size ◽  
Tumor Grade ◽  
S Phase ◽  
Phase Fraction ◽  
Nodal Metastases

scholarly journals TYPE OF ARTICLE: ORIGINAL ARTICLE ROLE OF CYTOKERATIN BIOMARKERS IN BREAST CARCINOMA

2016 ◽  
Vol 9 (6) ◽  
pp. 293
Author(s):  
Ritu Yadav
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Breast Carcinoma ◽  
Tumor Size ◽  
Hormone Receptor ◽  
Research Work ◽  
Tumor Grade ◽  
Lymph Node Status ◽  
Node Status ◽  
Number Of Patients

 ABSTRACT:Objective:Breast cancer comprises different biological subtypes having varied spectrum of clinical and pathological features with different prognostic and therapeutic implications. This study aimed at the identification of patients on the basis of cancer biomarkers and various clinicopathological parameters.Methods: Fresh paraffin embedded tissue block sample of three hundred fifty patients of breast carcinoma were collected during 2011-2014, from the Pathology department, Pt. B.D Sharma University of Heath Sciences Rohtak, Haryana and studied in detail to determine the correlation between hormone receptor status /cytokeratin (CK) expression along with clinicopathologicalfactors.Theimmunohistochemical assay of three hundred fifty patients of breast cancer was performed.Maximum number of patients (35%) were found in the age group of <40 years. Most of the patients were observed with the grade I (59%), tumor size 2-4.9cm (45%), <4 positive lymph node status for metastasis andinfiltrate ductal carcinoma type (93%).Triple positive and triple negative breast cancer types were studiedto identify the basal and luminal phenotypes on the basis of markers CK5, 14 and CK8/18 expression.Results:The expression of CK5 &14 was found to be significantly associated with tumor grade (P=0.001 and P=0.0001), tumor size (P= 0.001) respectively.Whereas CK8/18 expression did not reveal any significant association with tumor grade,size, lymph node status and histological type of breast carcinoma.Conclusion:In conclusion the prognostic and therapeutic value of research work would be examined and validated further on larger number of samples.Keywords: Breast carcinoma, biomarkers, clinicopathological factors, Cytokeratin, hormone receptor 

Sign in / Sign up

Export Citation Format

Share Document